



IFW

PATENT
Customer No. 22,852
Attorney Docket No. 03495.0300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Ali AMARA et al.) Group Art Unit: 1645
)
Application No.: 10/700,491) Examiner: Unassigned
)
Filed: November 5, 2003)
)
For: COMPOSITIONS COMPRISING) Confirmation No.: 6283
DC-SIGN BLOCKERS AND)
METHODS OF USING DC-)
BLOCKERS FOR PREVENTING)
OR TREATING DISEASES OF A)
MAMMAL, INCLUDING VIRAL)
INFECTIONS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents, including any copending patent applications, are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.


Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: May 26, 2004

By:


Kenneth J. Meyers
Reg. No. 25,146



INFORMATION DISCLOSURE CITATION

Atty. Docket No. 03495.0300	Appln. No. 10/700,491
Applicant Ali AMARA et al.	
Filing Date November 5, 2003	Group: 1642

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
WO 01/64752 A2	09/97/2001	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Curtis, Benson M. et al., "Sequence and Expression of a Membrane-Associated C-type Lectin that Exhibits CD4-Independent Binding of Human Immunodeficiency Virus Envelope Glycoprotein gp120," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 8356-8360 (1992).
	Geijtenbeek, Teunis B.H. et al., "Identification of DC-Sign, a Novel Dendritic Cell-Specific ICAM-3 Receptor that Supports Primary Immune Responses," <i>Cell</i> , Vol. 100, pp. 575-585 (2000).
	Halary, Franck et al., "Human Cytomegalovirus Binding to DC-Sign is Required for Dendritic Cell Infection and Target Cell <i>trans</i> -infection," <i>Immunity</i> , Vol 17, pp. 653-664 (2002).
	Tailleux, Ludovic et al., "DC-Sign is the Major Mycobacterium Tuberculosis Receptor on Human Dendritic Cells," <i>The Journal of Experimental Medicine</i> , Vol. 197, pp. 121-127 (2003).
	Patent Application No. 10/464,531 of Olivier NEYROLLES, Olivier SCHWARTZ, Ludovic TAILLEUX, and Philippe LAGRANGE, filed June 19, 2003 (identified by Attorney Docket No. 03495.0270)..
	Patent Application No. 10/700,507 of Ali AMARA, Frank HALARY, Julie DECHANET-MERVILLE, Jean-Francois MOREAU, Fernando ARENZANA-SEISDEDOS and Thierry DELAUNAY, filed November 5, 2003 (Identified by Attorney Docket No. 03495.0301).

Examiner	Date Considered
----------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.